Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ARWR
- CUSIP: N/A
- Web: www.arrowheadpharma.com
Capitalization:- Market Cap: $265.44 million
- Outstanding Shares: 74,772,000
Average Prices:- 50 Day Moving Avg: $2.49
- 200 Day Moving Avg: $1.89
- 52 Week Range: $1.20 - $8.09
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.38
- P/E Growth: -1.14
Sales & Book Value:- Annual Revenue: $22.73 million
- Price / Sales: 11.68
- Book Value: $1.21 per share
- Price / Book: 2.93
Profitability:- EBIDTA: ($47,970,000.00)
- Net Margins: -201.84%
- Return on Equity: -46.73%
- Return on Assets: -34.08%
Debt:- Debt-to-Equity Ratio: 0.03%
- Current Ratio: 3.84%
- Quick Ratio: 3.84%
Misc:- Average Volume: 1.24 million shs.
- Beta: 1.81
- Short Ratio: 10.59
Frequently Asked Questions for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
What is Arrowhead Pharmaceuticals' stock symbol?
Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
How were Arrowhead Pharmaceuticals' earnings last quarter?
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its earnings results on Thursday, August, 3rd. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company earned $9.34 million during the quarter, compared to analysts' expectations of $5.29 million. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. View Arrowhead Pharmaceuticals' Earnings History.
When will Arrowhead Pharmaceuticals make its next earnings announcement?
Where is Arrowhead Pharmaceuticals' stock going? Where will Arrowhead Pharmaceuticals' stock price be in 2017?
5 equities research analysts have issued 12-month target prices for Arrowhead Pharmaceuticals' stock. Their predictions range from $2.00 to $2.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $2.00 in the next year. View Analyst Ratings for Arrowhead Pharmaceuticals.
Who are some of Arrowhead Pharmaceuticals' key competitors?
Some companies that are related to Arrowhead Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), Karyopharm Therapeutics (KPTI), Progenics Pharmaceuticals (PGNX), Jounce Therapeutics (JNCE), Atara Biotherapeutics (ATRA), GlycoMimetics (GLYC), NantKwest (NK), Madrigal Pharmaceuticals (MDGL), AVEO Pharmaceuticals (AVEO), Selecta Biosciences (SELB), BioCryst Pharmaceuticals (BCRX), Mersana Therapeutics (MRSN), Urogen Pharma (URGN), Bellicum Pharmaceuticals (BLCM), Merus N.V. (MRUS), Corbus Pharmaceuticals Holdings (CRBP), Geron Corporation (GERN) and BioSpecifics Technologies Corp (BSTC).
Who are Arrowhead Pharmaceuticals' key executives?
Arrowhead Pharmaceuticals' management team includes the folowing people:
- Douglass B. Given M.D., Ph.D., Chairman of the Board
- Christopher Richard Anzalone Ph.D., President, Chief Executive Officer, Director
- Kenneth Allen Myszkowski, Chief Financial Officer
- Bruce D. Given M.D., Chief Operating Officer
- Patrick O'Brien, General Counsel
- Michael S. Perry Ph.D., Lead Independent Director
- Mauro Ferrari Ph.D., Independent Director
- Edward W. Frykman, Independent Director
Who owns Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.63%), LMR Partners LLP (0.39%), California Public Employees Retirement System (0.31%), Northern Trust Corp (0.30%), Schwab Charles Investment Management Inc. (0.21%) and Virtu KCG Holdings LLC (0.13%). Company insiders that own Arrowhead Pharmaceuticals stock include Douglas B Given, Kenneth Allen Myszkowski and Mauro Ferrari. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.
Who sold Arrowhead Pharmaceuticals stock? Who is selling Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Vanguard Group Inc., Bank of New York Mellon Corp and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
Who bought Arrowhead Pharmaceuticals stock? Who is buying Arrowhead Pharmaceuticals stock?
How do I buy Arrowhead Pharmaceuticals stock?
Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arrowhead Pharmaceuticals' stock price today?
One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $3.55.
MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.20) |
| Consensus Price Target: | $2.00 (43.66% downside) |
Analysts' Ratings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/18/2017 | William Blair | Upgrade | Market Perform -> Outperform | | High |  |
| 9/13/2017 | Chardan Capital | Reiterated Rating | Neutral | | Medium | |
| 9/15/2017 | Cantor Fitzgerald | Reiterated Rating | Hold | $1.00 -> $2.00 | High | |
| 8/4/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $2.00 | High | |
| 7/28/2017 | Piper Jaffray Companies | Reiterated Rating | Hold | $2.00 | Medium | |
(Data available from 9/23/2015 forward)
Earnings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)Earnings History by Quarter for Arrowhead Pharmaceuticals (NASDAQ ARWR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 12/12/2017 | | ($0.10) | | | | | N/A | |
| 8/3/2017 | Q3 2017 | ($0.13) | ($0.07) | $5.29 million | $9.34 million | View | Listen | |
| 5/3/2017 | Q2 2017 | ($0.12) | ($0.08) | $4.19 million | $8.99 million | View | Listen | |
| 2/6/2017 | Q117 | ($0.20) | ($0.17) | $13.24 million | $4.37 million | View | Listen | |
| 8/9/2016 | Q316 | ($0.37) | ($0.32) | $0.05 million | $39.58 million | View | N/A | |
| 5/10/2016 | Q216 | ($0.37) | ($0.35) | $0.26 million | $0.04 million | View | Listen | |
| 2/9/2016 | Q1 | ($0.41) | ($0.32) | $0.29 million | $0.04 million | View | N/A | |
| 12/14/2015 | Q415 | ($0.39) | ($0.42) | $0.14 million | $0.04 million | View | Listen | |
| 8/4/2015 | Q315 | ($0.38) | ($0.27) | $0.11 million | $0.12 million | View | N/A | |
| 5/11/2015 | Q214 | ($0.35) | ($0.33) | $110.00 million | $43.75 million | View | Listen | |
| 2/9/2015 | Q114 | ($0.32) | ($0.41) | $0.24 million | $0.17 million | View | N/A | |
| 11/25/2014 | Q413 | ($0.25) | ($0.33) | $0.04 million | $0.04 million | View | N/A | |
| 8/12/2014 | Q313 | ($0.22) | ($0.22) | $0.04 million | $0.04 million | View | N/A | |
| 5/6/2014 | Q2 2014 | ($0.18) | ($0.31) | $0.05 million | $0.04 million | View | N/A | |
| 2/4/2014 | Q4 | ($0.18) | ($0.33) | | | View | N/A | |
| 12/18/2013 | Q4 | ($0.23) | ($0.43) | | | View | Listen | |
| 5/9/2013 | Q2 2013 | | ($0.41) | | | View | N/A | |
| 2/13/2013 | Q1 2013 | | ($0.33) | | | View | N/A | |
| 12/20/2012 | Q4 2012 | | ($0.43) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)2017 EPS Consensus Estimate: ($0.21)
2018 EPS Consensus Estimate: ($0.68)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.22 | $0.22 | $0.22 |
| Q2 2017 | 2 | ($0.16) | ($0.11) | ($0.14) |
| Q3 2017 | 3 | ($0.15) | ($0.13) | ($0.14) |
| Q4 2017 | 3 | ($0.18) | ($0.10) | ($0.15) |
| Q1 2018 | 1 | ($0.11) | ($0.11) | ($0.11) |
| Q2 2018 | 1 | ($0.19) | ($0.19) | ($0.19) |
| Q3 2018 | 1 | ($0.19) | ($0.19) | ($0.19) |
| Q4 2018 | 1 | ($0.19) | ($0.19) | ($0.19) |
(Data provided by Zacks Investment Research)
Dividend History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)Insider Ownership Percentage: 4.57%
Institutional Ownership Percentage: 20.61%
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/14/2016 | Douglas B. Given | Director | Sell | 12,000 | $6.72 | $80,640.00 | |
| 8/23/2016 | Kenneth Allen Myszkowski | CFO | Sell | 6,900 | $8.00 | $55,200.00 | |
| 8/22/2016 | Kenneth Allen Myszkowski | CFO | Sell | 13,100 | $8.00 | $104,800.00 | |
| 12/30/2015 | Kenneth Allen Myszkowski | CFO | Sell | 23,347 | $6.13 | $143,117.11 | |
| 10/28/2015 | Mauro Ferrari | Director | Buy | 400 | $7.62 | $3,048.00 | |
| 10/9/2015 | Mauro Ferrari | Director | Buy | 1,900 | $6.19 | $11,761.00 | |
| 1/5/2015 | David L Lewis | Insider | Sell | 15,000 | $8.01 | $120,150.00 | |
| 10/15/2014 | Christopher Richard Anzalone | CEO | Buy | 16,000 | $6.32 | $101,120.00 | |
| 10/1/2014 | Charles Mckenney | Director | Sell | 2,500 | $14.70 | $36,750.00 | |
| 9/30/2014 | David L Lewis | Insider | Sell | 15,000 | $15.02 | $225,300.00 | |
| 9/26/2014 | Douglas B Given | Director | Sell | 2,000 | $15.24 | $30,480.00 | |
| 6/9/2014 | Charles Mckenney | Director | Sell | 22,000 | $14.32 | $315,040.00 | |
| 2/12/2014 | Kenneth Allen Myszkowski | CFO | Sell | 16,000 | $18.77 | $300,320.00 | |
| 2/7/2014 | Edward W Frykman | Director | Sell | 3,148 | $15.98 | $50,305.04 | |
(Data available from 1/1/2013 forward)
Headline Trends for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Latest Headlines for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
| Source: |
|
| Date | Headline |
|---|
 | Arrowhead Pharmaceuticals, Inc. to Post Q1 2018 Earnings of ($0.11) Per Share, William Blair Forecasts (ARWR)
www.americanbankingnews.com - September 20 at 9:22 AM |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Lifted to Outperform at William Blair
www.americanbankingnews.com - September 18 at 11:32 PM |
| Analyzing Arrowhead Pharmaceuticals (ARWR) and BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - September 17 at 2:31 AM |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Receives "Neutral" Rating from Chardan Capital
www.americanbankingnews.com - September 16 at 7:18 AM |
 | Here's What Caused Arrowhead Pharmaceuticals' Stock to Spike Today
finance.yahoo.com - September 15 at 4:23 PM |
| Cantor Fitzgerald Reaffirms Hold Rating for Arrowhead Pharmaceuticals, Inc. (ARWR)
www.americanbankingnews.com - September 15 at 7:28 AM |
| Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug Candidates
finance.yahoo.com - September 14 at 4:38 PM |
| Zacks: Analysts Expect Arrowhead Pharmaceuticals, Inc. (ARWR) Will Post Quarterly Sales of $7.32 Million
www.americanbankingnews.com - September 14 at 5:22 AM |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 13 at 5:06 AM |
| Zacks: Brokerages Anticipate Arrowhead Pharmaceuticals, Inc. (ARWR) to Announce -$0.13 Earnings Per Share
www.americanbankingnews.com - September 13 at 12:34 AM |
| ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : September 12, 2017
finance.yahoo.com - September 12 at 2:00 AM |
| Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 11 at 8:58 PM |
| Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q3, 2017 By the Numbers : September 8, 2017
finance.yahoo.com - September 8 at 10:05 PM |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - September 3 at 10:10 PM |
 | Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies - Business Wire (press release)
www.businesswire.com - September 1 at 9:40 PM |
| Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies
finance.yahoo.com - September 1 at 4:37 PM |
| FY2017 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Lifted by Analyst (ARWR)
www.americanbankingnews.com - August 28 at 3:38 AM |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - August 27 at 2:26 PM |
| $7.32 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (ARWR) This Quarter
www.americanbankingnews.com - August 27 at 5:50 AM |
| Contrasting Arrowhead Pharmaceuticals (ARWR) and Biopharmx Corp (BPMX)
www.americanbankingnews.com - August 19 at 8:44 AM |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 19 at 4:36 AM |
| Financial Comparison: Arrowhead Pharmaceuticals (ARWR) and Aldeyra Therapeutics (ALDX)
www.americanbankingnews.com - August 16 at 4:58 PM |
| $7.98 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) This Quarter
www.americanbankingnews.com - August 9 at 7:46 AM |
| Today’s Research Reports on Stocks to Watch: Horizon Pharma and Arrowhead Pharmaceuticals
finance.yahoo.com - August 8 at 3:56 PM |
| Zacks: Brokerages Expect Arrowhead Pharmaceuticals, Inc. (ARWR) to Announce -$0.14 EPS
www.americanbankingnews.com - August 7 at 8:32 AM |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given "Hold" Rating at Jefferies Group LLC
www.americanbankingnews.com - August 6 at 12:34 AM |
 | Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 9:24 PM |
| Edited Transcript of ARWR earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 4:22 PM |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Announces Earnings Results
www.americanbankingnews.com - August 4 at 4:20 PM |
| Investor Network: Arrowhead Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 3 at 5:29 PM |
| Arrowhead Reports Fiscal 2017 Third Quarter Results
finance.yahoo.com - August 3 at 5:29 PM |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:20 AM |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Earns Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - July 30 at 3:56 PM |
 | Popular biotech ETF on pace for steepest daily drop in a month - MarketWatch
www.marketwatch.com - July 27 at 4:07 PM |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results
finance.yahoo.com - July 27 at 4:06 PM |
| Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 25 at 10:27 AM |
| Zacks: Analysts Anticipate Arrowhead Pharmaceuticals, Inc. (ARWR) Will Announce Quarterly Sales of $5.29 Million
www.americanbankingnews.com - July 19 at 10:22 AM |
| Analysts Expect Arrowhead Pharmaceuticals, Inc. (ARWR) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 18 at 12:22 AM |
| ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 4:05 PM |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Sees Large Drop in Short Interest
www.americanbankingnews.com - June 29 at 7:13 AM |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 28 at 8:48 AM |
| Analysts Expect Arrowhead Pharmaceuticals, Inc. (ARWR) Will Post Quarterly Sales of $5.29 Million
www.americanbankingnews.com - June 23 at 1:42 PM |
| Zacks: Analysts Expect Arrowhead Pharmaceuticals, Inc. (ARWR) to Post -$0.13 Earnings Per Share
www.americanbankingnews.com - June 21 at 10:48 PM |
| Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - June 10 at 3:38 PM |
| Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
finance.yahoo.com - June 9 at 9:00 PM |
| Arrowhead Pharmaceuticals Inc (ARWR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 2 at 7:02 PM |
| $5.29 Million in Sales Expected for Arrowhead Pharmaceuticals Inc (ARWR) This Quarter
www.americanbankingnews.com - May 28 at 8:37 AM |
| Arrowhead Pharmaceuticals Inc (ARWR) Short Interest Down 12.3% in May
www.americanbankingnews.com - May 27 at 7:08 AM |
| Zacks: Analysts Anticipate Arrowhead Pharmaceuticals Inc (ARWR) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - May 26 at 4:32 PM |
| ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 26, 2017
finance.yahoo.com - May 26 at 3:57 PM |
Arrowhead Pharmaceuticals (ARWR) Chart for Saturday, September, 23, 2017
